Terms of Access and Use

By downloading, accessing, or viewing material from this website, you agree to the following Terms of Use. The research and analysis provided by Forensic Alpha Limited (“we”, “us”) is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy, sell, or hold any security, or any other form of regulated advice. We do not have, and do not seek to establish, any position (long or short) in the securities discussed in our research.

Our reports present our independent opinions on publicly available information, including but not limited to, company disclosures and financial statements. We aim to highlight potential risks, governance issues, or accounting practices that we believe merit further consideration by market participants. You agree to conduct your own research and due diligence, and to consult your own financial, legal, tax, and other professional advisers before making any investment or business decision. Use of our research is entirely at your own risk. In no event shall Forensic Alpha Limited or any affiliated party be liable for any direct, indirect, incidental, or consequential losses arising from your use of our materials.

The information we provide is based on sources we believe to be accurate and reliable at the time of publication, but it is provided “as is” without any representation or warranty of any kind, whether express or implied, including without limitation as to accuracy, completeness, or fitness for any particular purpose. All opinions expressed are subject to change without notice, and we do not undertake to update or supplement our research.

Access to our research is intended only for persons who are professional investors, institutional investors, or otherwise qualified to receive such information under applicable laws in their jurisdiction. In the United Kingdom, this includes (but is not limited to) persons falling within one or more of the categories described in Articles 19 (Investment Professionals) and 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. By proceeding to access our materials, you confirm that you meet the relevant criteria in your jurisdiction and are legally permitted to receive such information.

All content on this site is the intellectual property of Forensic Alpha Limited and is protected by applicable copyright laws. You agree not to reproduce, distribute, or transmit our research, in whole or in part, without our prior written consent, except by sharing a direct link to our website.

By clicking “I Agree” below, you confirm that you have read and agree to Forensic Alpha Limited’s Terms of Access and Use, that you are a professional or institutional investor (or otherwise qualified under the laws of your jurisdiction to receive such information), and that you understand our research does not constitute investment advice or a recommendation to buy, sell, or hold any security.
I Agree
back arrow

Pernod Ricard: A Cash Mirage

Thomas Beevers
Thomas Beevers
May 13, 2026
Copied!
share button icon

Pernod Ricard: A Cash Mirage

Pernod Ricard brought forward its H1 results to Thursday last week as it downgraded guidance for the full year.  The company now expects a low single-digit decline in organic sales for the full year, driven by particularly weak markets in the US and China. The market was relatively relaxed about the downgrade however, since much of the weakness was already anticipated, while underlying margins were robust.

The company also celebrated a significant improvement  in cash flow, which was up +46% versus last year at EUR 440m. Management cited strong discipline on cost (A&P was down) and a focus on cash generation (see extract from the management presentation below).

On the call, the EVP of Finance, Helene de Tissot, was quick to highlight the achievement:

“This is obviously a very strong focus, and we have improved free cash flow by circa EUR 150 million versus December '23. So this year, this first half, it amounts to EUR 440 million. We are continuously optimizing ordinary working capital, with this semester notable improvement in finished good inventory level”

However, a closer look at the balance sheet in the press release shows a massive increase in the use of factoring, from EUR 1.1bn at the end of 2024 to EUR 1.6bn at the end of December 24 (see extract below). The increase in factoring would have benefited cash flow by nearly EUR 500m. In other words if the sale of receivables had stayed at the same level, then cash flow would in fact have been negative in the first half. It would appear this was not an operational improvement, but the impact of financial engineering.

To be fair, the use of factoring is clear if you read to the end of the press release, but it was not discussed at all in the text, nor on the call. We question the degree to which the market has really picked up on this. In the context of falling profits and rising debt, the lack of underlying cash flow should be concerning to investors.

Note that stripping out the sold receivables we see that “Trade receivables before factoring/ securitization” has moved up in the past 6 months from 2.6bn at June 24 to 3.8bn in December 24. It is also higher than the same point in June 23 despite falling sales. This is concerning in itself as it raises questions about collectability, particularly when we consider an existing flag dating from the FY24 financial statements on ageing of receivables. This flag showed a sharp increase in receivables past due more than 30 days from 5% to 14%.

While there is nothing inherently wrong with factoring receivables as a form of financing, we think it’s somewhat disingenuous of management to claim that strong cash flow was the result of an improvement in working capital. The sharp growth in receivables, the deterioration in the ageing profile and the underlying weak cash flow paint a somewhat different picture once we adjust for these sales.

If you are an institutional investor, you can sign up to our email list here
arrow icon
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Institutional investors are eligible for a 7-day free trial.

Our machine intelligence helps Portfolio Managers to spot critical red flags hidden deep within the financial statements and governance disclosures.

Request Demo

Forensic Alpha uses proprietary machine intelligence to identify risks hidden deep within the financial statements and governance disclosures.

Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB

Forensic Alpha US INC
12 East 49th Street
New York
NY 10017
USA

forensic alpha
Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB
Forensic Alpha US INC
12 East 49th Street
New York NY 10017
USA
Forensic Alpha Limited is authorised and regulated by the Financial Conduct Authority (Reference number: 763770)
© 2022 Forensic Alpha. All rights reserved.  Terms & Conditions  |  Privacy Policy  |  Cookie policy
twitter profilelinkedin profile